医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Initial Results Positive for CelGro® in Human Nerve Regeneration

2017年02月22日 AM09:44
このエントリーをはてなブックマークに追加


 

PERTH, Australia

Regenerative medicine company Orthocell is pleased to announce positive initial safety and tolerability results for its CelGro® collagen-based medical device, in a clinical study examining its use to augment the repair of nerve damage.

The first two patients treated in this pivotal trial had previously suffered traumatic peripheral nerve injury resulting in the inability to bend their elbow and significantly impacting basic activities of daily living. An interim review at 20 days post operation for the first two patients to receive CelGro® nerve regeneration treatment demonstrated that CelGro® is safe and was well tolerated with no inflammatory reactions or complications.

Orthocell Managing Director Paul Anderson said: “This initial assessment is very positive and represents an important step forward in the development of CelGro® in the very important area of human nerve regeneration. CelGro® allows for suture-less reconnection of the damaged nerve while guiding nerve regeneration and accelerating the healing process.”

Peripheral nerve injury is most commonly caused by accidents or other trauma and in the US alone over 20 million people are affected each year, at a cost of approximately $150 billion in annual health care dollars.

CelGro® is a biological medical device used in a variety of orthopaedic and general reconstructive surgical applications. Orthocell is undertaking a wide range of clinical studies using CelGro® to augment tendon, nerve and cartilage repair as well as to guide and promote bone regeneration.

Orthocell has submitted CelGro® for first regulatory approval in Europe and expects to receive notice of approval of its CE Mark application in Q1 2017. Orthocell has also submitted a 510(k) application for FDA regulatory clearance of CelGro® in the US.

Receipt of these approvals will enable commercialisation of CelGro® products to commence in Europe and US, as well as trigger applications for other regulatory approvals in Australia and Japan in 2017.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170221006825/en/

CONTACT

General enquiries
Orthocell Limited
Paul
Anderson,
+61 8 9360 2888
Managing Director
paulanderson@orthocell.com.au
or
Investor
and Media enquiries

WE Buchan
Ben Walsh, +61
411 520 012
bwalsh@buchanwe.com.au

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Sixteen Healthcare Groups Make Major Commitments at 2nd Annual Patient Safety Rally in Taiwan
  • CBT Pharmaceuticals and CrystalGenomics Announce Partnership for Co-development of Global Immuno-Oncology Therapy
  • Porton Pharma SolutionsとCodexisがグローバルな提携を発表
  • 重庆博腾制药科技股份有限公司与Codexis开启全球伙伴关系
  • EpimAb Biotherapeutics and Zhejiang Teruisi Biopharmaceutical Announce Development Collaboration on Epimab’s FIT012 Bispecific Antibody Program